. Intrinsic A 1 adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am J Physiol Heart Circ Physiol 279: H2166-H2175, 2000.-We assessed the role of A 1 adenosine receptor (A 1 AR) activation by endogenous adenosine in the modulation of ischemic contracture and postischemic recovery in Langendorff-perfused mouse hearts subjected to 20 min of total ischemia and 30 min of reperfusion. In control hearts, the rate-pressure product (RPP) and first derivative of pressure development over time (ϩdP/dt) recovered to 57 Ϯ 3 and 58 Ϯ 3% of preischemia, respectively. Diastolic pressure remained elevated at 20 Ϯ 2 mmHg (compared with 3 Ϯ 1 mmHg preischemia). Interstitial adenosine, assessed by microdialysis, rose from ϳ0.3 to 1.9 M during ischemia compared with ϳ15 M in rat heart. Nonetheless, these levels will near maximally activate A 1 ARs on the basis of effects of exogenous adenosine and 2-chloroadenosine. Neither A 1 AR blockade with 200 nM 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) during the ischemic period alone nor A 1 AR activation with 50 nM N 6 -cyclopentyladenosine altered rapidity or extent of ischemic contracture. However, ischemic DPCPX treatment significantly depressed postischemic recovery of RPP and ϩdP/dt (44 Ϯ 3 and 40 Ϯ 4% of preischemia, respectively). DPCPX treatment during the reperfusion period alone also reduced recovery of RPP and ϩdP/dt (to 44 Ϯ 2 and 47 Ϯ 2% of preischemia, respectively). These data indicate that 1) interstitial adenosine is lower in mouse versus rat myocardium during ischemia, 2) A 1 AR activation by endogenous adenosine or exogenous agonists does not modify ischemic contracture in murine myocardium, 3) A 1 AR activation by endogenous adenosine during ischemia attenuates postischemic stunning, and 4) A 1 AR activation by endogenous adenosine during the reperfusion period also improves postischemic contractile recovery.
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contracture; stunning THERE IS EVIDENCE THAT ADENOSINE may function as an endogenous cardioprotectant during ischemia-reperfusion. Activation of cardiovascular adenosine receptors by exogenously applied adenosine agonists protects from ischemic injury (4, 9, 31, 32) , improves functional recovery during reperfusion (9, 11, 12, 30, 35, 39, 42, 43) , and enhances metabolic recovery (49) . There is also evidence that endogenous adenosine improves functional and metabolic tolerance to ischemia-reperfusion (2, 23, 24, 34, 47, 48) . Although most data favor a key role for the A 1 adenosine receptor (A 1 AR) in cardioprotection (11, 24, 30, 32, 33, 34, 48) , some studies suggest that the recently characterized A 3 receptor may mediate protection (40, 42, 44) , and there is also evidence for beneficial effects of A 2 receptor activation during ischemia-reperfusion (7, 35, 38, 43) . The temporal characteristics of adenosine-mediated protection are also unclear. Some studies suggest that activation of adenosine receptors before and during ischemia is essential for reduction of stunning in vivo and in vitro (37, 39, 43, 46) , whereas others demonstrate A 1 AR protection during early reperfusion (33) .
Although such studies verify beneficial receptor-mediated protection with exogenous adenosine agonists, the role of endogenous adenosine in ameliorating injury during ischemia and/or reperfusion is much less clear. Evidence of A 1 -mediated cardioprotection with exogenous agonists before and during ischemia and of A 2 agonists during reperfusion does not demonstrate a role for intrinsic A 1 or A 2 receptor activation by endogenous adenosine at these times. The purpose of the present study was to delineate between cardioprotective effects of A 1 AR activation by endogenous adenosine during the ischemic episode itself versus during the postischemic period. Langendorff-perfused murine hearts were subjected to global ischemia-reperfusion in the absence and presence of a potent and selective A 1 AR antagonist [200 nM 8-cyclopentyl-1,3-dipropylxanthine (DPCPX)]. To reduce endogenous activation of A 1 ARs during ischemia, DPCPX was applied during the ischemic episode alone. To reduce endogenous activation of A 1 ARs during reperfusion only, a second group received DPCPX throughout the postischemic period alone. In addition, we examined release of adenosine into the interstitial compartment and the potency of adenosine at A 1 ARs because there is presently no information regarding myocardial adenosine levels during ischemia in the increasingly studied murine heart.
MATERIALS AND METHODS
Langendorff-perfused murine heart model. Hearts (165 Ϯ 36 mg wet heart wt, n ϭ 70) were isolated from 7-to 12-wk-old male C57/Bl6 mice (22-27 g body wt) anesthetized with 60 mg/kg pentobarbital sodium given intraperitoneally. The aorta was rapidly cannulated, and the coronary circulation was perfused at a constant pressure of 80 mmHg with modified Krebs-Henseleit buffer containing (in mM) 120 NaCl, 22 NaHCO 3 , 4.7 KCl, 2.5 CaCl 2 , 1.2 MgCl 2 , 1.2 KH 2 PO 4 , 15 glucose, and 0.5 EDTA. The buffer was equilibrated with 95% O 2 -5% CO 2 at 37°C, giving a pH of 7.4 and a perfusion fluid PO 2 Ն 640 mmHg. The buffer was initially passed through a 5-filter after preparation and was filtered through an in-line 0.45-Sterivex-HV filter cartridge (Millipore, Bedford, MA) within the perfusion apparatus. The left ventricle was vented with a polyethylene apical drain, and a fluidfilled balloon constructed of polyvinyl chloride plastic film was inserted into the left ventricle via the mitral valve. The balloon was connected to a P23 XL pressure transducer (Viggo-Spectramed, Oxnard, CA) by a fluid-filled polyethylene tube. The balloon was inflated using a 500-l Hamilton threaded plunger syringe (Hamilton, Reno, NV) to give an end-diastolic pressure of 4 mmHg. Coronary flow was monitored via a cannulating Doppler flow probe (1N probe; Transonic Systems, Ithaca, NY) located in the aortic perfusion line and connected to a T206 flowmeter (Transonic Systems). Functional data were recorded at a sampling rate of 1 kHz on a four-channel MacLab data acquisition system (ADInstruments, Castle Hill, Australia) connected to an Apple computer. The ventricular pressure signal was digitally processed to yield peak systolic pressure, diastolic pressure, first derivative of pressure development or relaxation over time (ϮdP/dt), and heart rate. After the hearts were instrumented, they were immersed in perfusate inside a waterjacketed bath maintained at 37°C. The temperature of coronary perfusion fluid was continuously assessed by a needle thermistor at the top of the aortic cannula.
Cardiac microdialysis. To examine interstitial adenosine levels, microdialysis cannulas were implanted in the left ventricular wall of a subset of perfused mouse hearts (n ϭ 6), as described by our laboratory in detail previously for rat heart (19) (20) (21) (22) . For the purposes of comparison, a group of rat hearts was also perfused as described for mouse hearts, and microdialysis probes were implanted (n ϭ 8). Specifically, purpose-built cannulas were constructed of 4-mm lengths of dialysis membrane (300-m outside diameter, 5000 Dalton cut-off) cannulated at both ends with highly flexible plastic/ fused silica MicroFil tubing with an outside diameter of 144 m (World Precision Instruments, Sarasota, FL). The microdialysis cannulas were located within the free wall of the left ventricle approximately midway between base and apex, and the position of the cannula was adjusted to centrally locate the dialysis membrane window within the ventricular wall (19) (20) (21) (22) . Cannulas were perfused with degassed perfusion fluid at 2 l/min, and consecutive 10-min collections of dialysate were made throughout perfusion periods, whereas consecutive 5-min collections of dialysate were made during the ischemic episode. Aliquots of dialysate were frozen at Ϫ80°C until analysis by HPLC as described by our laboratory in detail previously (19) (20) (21) (22) . Preliminary studies revealed no differences in myocardial enzyme leakage (creatine kinase, lactate dehydrogenase) between hearts with and without probes under aerobic conditions (data not shown).
Analysis of myocardial metabolic state. For assessment of myocardial metabolic state under aerobic conditions, total myocardial ATP, phosphocreatine (PCr), and creatine (Cr) levels were determined in freeze-clamped mouse hearts perfused over a 30-min stabilization period (n ϭ 6), as described by our laboratory previously (23) . Powdered frozen tissue was extracted with 0.6 M perchloric acid, and neutralized samples were analyzed for ATP together with PCr and Cr as outlined by our laboratory in detail previously (19, 20, 23, 25) . Cytosolic concentrations were calculated from total tissue levels with the use of an intracellular volume of 0.47 ml/g wet wt, which we determined recently for Langendorff-perfused rat heart (25 (23, 25) .
Experimental protocol. In initial studies, stability of the hearts and metabolic state under aerobic conditions were assessed. To assess functional stability in the isovolumically contracting Langendorff-perfused mouse heart, a group of hearts (n ϭ 5) was perfused under aerobic conditions for a period of 100 min. Function was monitored over this period, and the decline in developed pressure, heart rate, and coronary flow was assessed relative to function measured immediately after instrumentation of the hearts. To assess basal metabolic state, a group of hearts stabilized for 30 min under aerobic conditions was freeze-clamped and analyzed as described above (n ϭ 6).
For ischemia studies, all hearts were initially stabilized for 30 min after which they were untreated or treated with drug for a period of 10 min. Global normothermic ischemia for 20 min was then initiated by cross clamping of the aortic cannula. This was followed by 30 min of aerobic reperfusion at a pressure of 80 mmHg. Hearts were permitted to beat at intrinsic rates throughout. Control hearts received no drug treatment at any time (n ϭ 6). A parallel set of experiments was undertaken in a group of mouse (n ϭ 6) and rat hearts (n ϭ 8) with microdialysis probes in place to monitor interstitial purine levels during ischemia. To assess the possibility that A 1 AR activation by endogenous adenosine during the ischemic period alone modifies functional recovery, a subset of hearts (n ϭ 7) received the potent A 1 specific antagonist DPCPX during ischemia but not reperfusion. A 20 M stock solution was infused at 1% of coronary flow to give a final perfusate concentration of 200 nM. DPCPX infusion was initiated 10 min before onset of the 20-min ischemic insult. Infusion was stopped at the onset of ischemia. To assess the possibility that A 1 AR activation by endogenous adenosine during the reperfusion period alone modifies functional recovery, a subset of hearts (n ϭ 6) was treated with 200 nM DPCPX throughout the 30-min reperfusion period. DPCPX infusion was initiated 30 s before reintroduction of coronary perfusion.
To assess the potential effects of selective A 1 AR activation on ischemic contracture, a subset of hearts (n ϭ 6) was subjected to ischemia alone and treated with 50 nM N 6 -cyclopentyladenosine (CPA) starting 10 min before onset of the 20-min ischemic insult. To examine the impact of a modest (10%) elevation in preischemic heart rate on functional responses to ischemia-reperfusion, a subset of hearts (n ϭ 10) was switched from an intrinsic heart rate of 386 Ϯ 23 to 423 Ϯ 18 beats/min 10 min before the global ischemic insult. Pacing was stopped on initiation of ischemia, as described by our laboratory previously (34) .
To determine whether levels of interstitial adenosine achieved during ischemia and reperfusion would exert significant functional effects at myocardial A 1 ARs, a subset of hearts was treated with the endogenous agonist adenosine (n ϭ 5) and the nonmetabolized and transported nonspecific A 1 /A 2 agonist 2-chloroadenosine (n ϭ 6). Agonists were applied at concentrations of 0.03-3.0 M. Changes in heart rate and coronary flow were measured at each concentration. Finally, to verify the antagonistic properties of DPCPX, the compound was infused into hearts (n ϭ 8), and chronotropic responses to 1 M adenosine or 2-chloroadenosine were measured and compared with responses in untreated hearts.
The potency of adenosine and 2-chloroadenosine was assessed by calculation of EC 50 values from individual concentration-response curves for heart rate or resistance changes by use of the following single-site four-parameter logistic equation
where A is the response at zero dose (i.e., the preinfusion heart rate or resistance), B is the response at infinite dose (constrained to a 100% reduction in heart rate), and [agonist] is agonist concentration. The equation was fit to raw data by use of the Statistica data analysis program (Statsoft, Tulsa, OK).
Statistical analysis. All results are expressed as means Ϯ SE. Functional parameters under baseline conditions were statistically analyzed by a one-way analysis of variance. Functional responses to ischemia-reperfusion in different treatment groups were analyzed by multiway analysis of variance for repeated measures. When significance was detected, a Newman-Keuls post hoc test was employed for individual comparisons. For all tests, statistical significance was accepted for P Ͻ 0.05.
RESULTS
Baseline function and stability in perfused mouse hearts. Time-course studies revealed a progressive reduction in left ventricular pressure development equivalent to 74 Ϯ 3% of the initial value over a 100-min period of aerobic perfusion. Heart rate remained stable throughout and was 99 Ϯ 3% of baseline after 100 min of perfusion. Coronary flow was also stable, increasing very modestly with time to a value of 111 Ϯ 5% at 100 min. As a result of the gradual fall in developed pressure, the rate-pressure product declined to 73 Ϯ 2% after 100 min of perfusion. The baseline coronary flow rate (18-20 ml ⅐ min Ϫ1 ⅐ g Ϫ1 ) was subsequently shown to be ϳ50% of maximal flows observed during A 1 AR activation with 2-chloroadenosine. Baseline functional measurements from hearts with and without dialysis probes are shown in Table 1 .
Metabolically, the perfused mouse hearts were relatively highly energized ( (25), we calculated a Gibbs free energy of ATP hydrolysis (⌬G ATP ) of 61.3 kJ/mol for mouse heart, exceeding values measured in rat myocardium by our laboratory previously (e.g., Ref. 24 ) and reflecting efficient ATP maintenance at the expense of ADP (and P i ).
Response to ischemia-reperfusion in control hearts. Global normothermic ischemia rapidly abolished contractile function in all hearts within 120-180 s. The rate-pressure product and ϩdP/dt fell to ϳ3% of baseline after 60 s and to Ͻ1% after 120 s (Fig. 1) . A pronounced contracture developed very rapidly during ischemia, and significant diastolic dysfunction remained throughout the reperfusion period (Fig. 1A) . On reperfusion, the diastolic pressure initially fell to ϳ30 mmHg during the first 1 min, rose to ϳ35 mmHg after 2 min, and then gradually fell to a value of 20 mmHg after 30 min of reperfusion (Fig. 1A) . Recovery of the rate-pressure product displayed a similar pattern during reperfusion, with an early peak at 1-5 min before a gradual recovery throughout reperfusion (Fig.  1B) . Recovery of ϩdP/dt paralleled the recovery of the rate-pressure product (Fig. 1C) . Heart rate and coronary flow ultimately recovered to 98 Ϯ 3 and 95 Ϯ 7% of preischemic levels, respectively.
Effects of A 1 AR antagonism during ischemia versus reperfusion. Preischemic contractile function was unaltered by DPCPX treatment with diastolic pressures of 3 Ϯ 1 and 2 Ϯ 1 mmHg in control and DPCPXtreated hearts, respectively, and left ventricular developed pressures of 161 Ϯ 4 and 154 Ϯ 7 mmHg in control and DPCPX-treated hearts, respectively (Fig.  1) . Contractility assessed by ϩdP/dt was also unaltered in DPCPX-pretreated hearts (4,762 Ϯ 284 mmHg/s) compared with control hearts (5,070 Ϯ 282 mmHg/s). Values are means Ϯ SE; n ϭ no. of hearts. Parameters were measured after 40 min of aerobic perfusion in hearts beating at intrinsic heart rates. ϮdP/dt, first derivative of pressure development or relaxation over time. No significant differences existed between the 2 groups. However, preischemic DPCPX significantly elevated heart rate from 372 Ϯ 12 to 420 Ϯ 9 beats/min (P Ͻ 0.05).
Treatment of hearts with 200 nM DPCPX before and during the ischemic episode itself resulted in significant depression of contractile recovery (rate-pressure product and ϩdP/dt) and produced a consistent elevation in postischemic diastolic pressure (Fig. 1) . Treatment of hearts with DPCPX throughout the reperfusion period alone also significantly reduced recovery of the rate-pressure product and ϩdP/dt but failed to alter left ventricular diastolic pressure (Fig. 1) . Final contractile recoveries in hearts receiving DPCPX preischemia or during reperfusion alone were similar at the end of the 30-min reperfusion period, whereas early recovery (between 10-20 min) was impaired to a greater extent in hearts receiving A 1 AR antagonist during ischemia (Fig. 1) . Both heart rate and coronary flow recovered to between 95 and 100% of preischemic levels in all groups. Preischemic treatment with DPCPX failed to alter the initial decline in contractile function during ischemia (Fig. 1) and did not modify the rate and extent of contracture development during ischemia (Fig. 2) . Similarly, treatment of hearts with 50 nM CPA failed to alter contracture development during ischemia (Fig. 2) .
To examine the potential impact of the DPCPXdependent elevation in preischemic heart rate (from 372 Ϯ 12 to 420 Ϯ 9 beats/min), we studied the effects of a direct increase in preischemic heart rate from 386 Ϯ 23 to 423 Ϯ 18 beats/min (i.e., a 10% elevation in heart rate). As shown in Figs. 1 and 2 , this elevation in rate had no effect on initial changes in contractile function during ischemia, development of ischemic contracture, or postischemic functional recovery. Changes in interstitial adenosine and effects of adenosine treatment. Microdialysis studies revealed that interstitial adenosine, inosine, and hypoxanthine levels rise dramatically during global ischemia in the mouse heart (Fig. 3) . Adenosine initially rose to 580% of baseline levels between 5 and 10 min of ischemia before plateauing and then falling slightly in the final 5 min of ischemia. Adenosine then rapidly recovered to preischemic levels during reperfusion. Interestingly, both inosine and hypoxanthine peaked after adenosine (i.e., between 15 and 20 min). On the basis of 20 Ϯ 3% recovery for microdialysis probes of the length used in mice in this study (i.e., relative recovery of external adenosine in bench experiments), the interstitial adenosine level approximates 0.3 Ϯ 0.1 M under normoxic conditions in the mouse heart and reaches a peak of 1.9 Ϯ 0.2 M during global ischemia. A slightly differing pattern of release was observed for adenosine, inosine, and hypoxanthine in rat hearts, and final levels were much higher (Fig. 3) . Adenosine rose to a peak value Ͼ3,500% of preischemic levels between 10 and 15 min of ischemia and then began to plateau. Again, inosine and hypoxanthine changes lagged slightly behind those for adenosine, with peak levels achieved between 15 and 20 min of ischemia. On the basis of 37 Ϯ 4% recovery of adenosine for microdialysis probes of the length used in rats, the interstitial adenosine level is calculated to be 0.4 Ϯ 0.1 M under normoxic conditions and reaches values of 14.3 Ϯ 1.0 and 15.1 Ϯ 1.6 m at 10-15 min and 15-20 min of global ischemia, respectively. These values were significantly higher than those in mouse heart (P Ͻ 0.05).
Because there is minimal information regarding functional efficacy of adenosine in murine hearts, we examined responses to adenosine and the nonmetabolized analog 2-chloroadenosine at concentrations approximating those estimated during ischemia (1.0-2.0 M) and early reperfusion (0.2-0.3 M). Infusion of similar levels of the more potent 2-chloroadenosine resulted in significant reductions in heart rate by ϳ50% (at 0.1-0.3 M) to ϳ90% (at 1.0-3.0 M) (Fig.  4) . Infusion of the rapidly catabolized endogenous agonist also resulted in significant A 1 receptor activation even at the lower doses studied (i.e., reduced rate by 15-20% at 0.1-0.3 M), with a pronounced bradycardia at 1.0-3.0 M (ϳ50% reduction in rate). EC 50 values for A 1 AR-mediated bradycardia were 2.9 Ϯ 0.4 M for infused adenosine and 0.4 Ϯ 0.2 M for 2-chloroadenosine. Treatment with DPCPX fully blocked the negative chronotropic effects of 3 M adenosine and 2-chloroadenosine (Fig. 4) . Both agonists produced significant vasodilatation. Maximal coronary flows achieved during infusion of adenosine and 2-chloroadenosine were 33.5 Ϯ 3.8 and 36.4 Ϯ 3.9 ml ⅐ min Ϫ1 ⅐ g Ϫ1 , respectively.
DISCUSSION
The present study demonstrates that 20 min of global normothermic ischemia in murine heart produces 40-50% depression of contractile function after 30 min of reperfusion and results in a transient elevation in interstitial adenosine to physiologically active levels (ϳ2 M). Selective A 1 AR antagonism both during ischemia itself and during the reperfusion period alone impaired contractile recovery. Thus A 1 AR acti- vation by endogenous adenosine significantly improves postischemic function in murine myocardium, with beneficial effects mediated by receptor activation both during the preceding ischemic insult and during the postischemic period. We obtain no evidence for modification of ischemic contracture by exogenous or endogenous activation of A 1 ARs during ischemia in the mouse heart.
Interstitial adenosine levels and adenosine responses in murine heart. No data exist regarding interstitial adenosine in normoxic or ischemic murine heart. Our data (Fig. 3) indicate that basal interstitial adenosine levels are similar to those measured in isolated rat hearts (19, 20, 22) and in situ rat myocardium (21) . These data are consistent with the recent observation that coronary venous adenosine in mouse heart approximates venous adenosine in the rat heart (15). Curiously, despite a higher basal metabolic rate and observations of profound reductions in cellular ATP in ischemic mouse heart (23), extracellular adenosine levels achieved during ischemia are much lower in mouse heart (i.e., ϳ2 M) versus rat heart (i.e., ϳ15 M). Reasons for this difference are not clear from the present study. However, Arch and Newsholme (3) have documented lower 5Ј-nucleotidase activity and higher adenosine kinase activity in mouse versus rat heart. Consequently, catabolism of 5Ј-AMP to adenosine may be reduced and recycling of adenosine to 5Ј-AMP enhanced in murine myocardium, leading to lower extracellular adenosine during increased ATP catabolism. Such a scheme would be consistent with our observation of reduced adenosine accumulation during ischemia (Fig. 3) , despite marked hydrolysis of ATP in the mouse heart (23) . An adaptation such as this may serve to protect adenine nucleotide levels in rapidly respiring murine myocardium.
Almost no data exist regarding responses to adenosine in murine heart. As shown in Fig. 4 , adenosine and 2-chloroadenosine dose dependently dilate coronary vessels (A 2 mediated) and inhibit intrinsic heart rate (A 1 mediated) in mouse heart. On the basis of concentration-response profiles for adenosine and the stable analog 2-chloroadenosine, we predict that basal levels of interstitial adenosine (ϳ0.3 M) may modestly depress resting heart rate in mouse hearts. Validating this prediction, treatment of normoxic hearts with 200 nM DPCPX significantly elevated resting rate from ϳ370 to 420 beats/min. On the basis of sensitivities to adenosine and 2-chloroadenosine, we also predict that interstitial adenosine levels achieved during ischemia (ϳ2 M) will substantially activate myocardial A 1 ARs. Exogenously infused adenosine at 1-3 M reduced rate by 35-55%, whereas the same levels of 2-chloroadenosine reduced rate by 70-90% (Fig. 4) . Because adenosine is rapidly transported and catabolized, A 1 AR activation by 1-3 M infused adenosine underestimates activation by 1-3 M interstitial adenosine. On the other hand, 2-chloroadenosine is not catabolized, readily equilibrates across vascular and interstitial compartments, and is slightly more potent than adenosine at A 1 ARs. Thus A 1 AR-mediated effects of 1-3 M interstitial adenosine will be greater than effects of 1-3 M infused adenosine and less than those of 1-3 M 2-chloroadenosine (Fig. 4) . Collectively, data for interstitial adenosine levels (Fig. 3 ) and sensitivity to adenosine (Fig. 4) indicate that A 1 ARs will be substantially activated during ischemia and will also be activated during the reperfusion period. Treatment with a potent and selective A 1 AR antagonist should therefore unmask functional effects of intrinsic A 1 AR activation in ischemic and/or postischemic myocardium.
Lack of effect of A 1 AR blockade or activation on ischemic contracture. Although it is not known whether ischemic contracture is a direct indicator of irreversible ischemic damage, contracture is generally considered to reflect ischemic injury and may contribute to impaired recovery on reperfusion (29, 36) . Studies employing exogenous adenosine agonists lend credence to the notion that A 1 ARs attenuate contracture development (12, 27, 31, 32) . Moreover, we have recently shown that pronounced overexpression of myocardial A 1 ARs inhibits ischemic contracture (34) . Contracture is thought to occur when anaerobic glycolytic flux and ATP generation fall to a threshold level (29, 36) , and there is evidence that A 1 ARs modulate glycolysis, although there are observations of both accelerated (1, 10, 27) and reduced glycolysis (11, 12, 14) . In the present study, selective A 1 AR antagonism with 200 nM DPCPX had no effect on rapidity or extent of ischemic contracture (Fig. 2) . Additionally, 50 nM CPA (a level that almost maximally reduces heart rate) failed to alter contracture development. Thus A 1 AR activation by endogenous adenosine or exogenous agonists does not modify contracture in mouse, or, alternatively, DPCPX is unable to competitively block a supramaximal A 1 AR-mediated response. A near-maximal response is consistent with the levels of interstitial adenosine achieved (Fig. 3) and with the lack of effect of an A 1 AR agonist observed here (Figs. 1 and 2 ) and previously in mouse and rat (16, 34) . In terms of antagonist treatment, DPCPX was applied at a concentration 200-fold higher than its inhibitor constant (K i ) for A 1 ARs, and we demonstrate practically that DPCPX effectively blocks A 1 AR responses to adenosine and 2-chloroadenosine when they are applied at levels (3 M) approximating or exceeding adenosine concentrations attained during ischemia (ϳ2 M) (Fig. 4) . Because 2-chloroadenosine is more potent than adenosine, our data verify that DPCPX will effectively antagonize A 1 AR effects mediated by lower levels of adenosine achieved during ischemia. The fact that functional recovery was depressed after ischemic DPCPX treatment (Fig. 1) also demonstrates antagonism of A 1 ARs during ischemia. We therefore conclude that the lack of effect of DPCPX (and CPA) indicates that A 1 AR activation by endogenous or exogenous adenosine during ischemia does not modify contracture in murine myocardium.
This conclusion appears to contrast with previous studies in which exogenous adenosine agonists and/or antagonists modify ischemic contracture (12, 27, 31, 32 ). However, effects of exogenous agonists do not reflect a role for endogenous adenosine, and many of these earlier studies employed agonists [adenosine, R-N 6 -phenylisopropyl adenosine (R-PIA)] that activate both A 1 and A 3 receptors at the levels used (e.g., Refs. 31 and 32). Recent evidence suggests that the A 3 receptor may be protective (40, 42, 44) . Therefore, effects of exogenous agonists may not occur via A 1 ARs. Similarly, when antagonists have been employed, they are typically nonselective (e.g., 8-sulfophenyltheopylline, BW-1433U) and are applied at levels sufficient to block A 1 , A 2 , and A 3 adenosine receptors (31, 32, 34) . For example, levels of BW-1433U previously employed are 5-to 10-fold higher than the A 3 receptor K i (26) , and Lasley and colleagues (32) report that this drug also blocked A 2 -mediated coronary vasodilation. Consequently, exaggeration of contracture with these antagonists may reflect A 3 rather than A 1 AR inhibition. Supporting this suggestion, selective A 3 activation reduces injury during (40) and after ischemia (42, 44) . Surprisingly, we are aware of only one prior study of the effects of a selective A 1 AR antagonist during ischemia in the absence of exogenous adenosine agonists (16) . In agreement with our observations, Grover et al. (16) found that A 1 AR-selective DPCPX failed to alter contracture in the rat heart in the absence of adenosine agonists. This is also consistent with the observation that A 1 AR antagonism with DPCPX fails to alter the effects of nucleoside transport blockade on ischemic contracture (17) . Collectively, the lack of effect of A 1 AR blockade on contracture in mouse ( Figs. 1 and 2 ) and rat (16, 17) , acceleration of contracture with nonselective A 1 /A 3 antagonists (31, 32, 34) , delay of contracture with high levels of adenosine and R-PIA activating A 1 and A 3 receptors, blockade of the latter effect with nonselective A 1 /A 3 antagonists (32), and a lack of effect of A 2 activation on contracture (30) are all consistent with inhibition of ischemic contracture by an adenosine receptor other than the A 1 subtype.
A final possibility, consistent with levels of adenosine attained during ischemia, is that delayed contracture after nonselective adenosine agonist pretreatment (32) reflects activation of adenosine receptors before but not during ischemia (i.e., a "preconditioning-like" effect). It is difficult to reconcile cardioprotection by exogenous agonists with the supramaximal levels of endogenous adenosine attained during ischemia, as shown here (Fig. 3) and previously (19, 20) . Supporting this possibility, transient activation of adenosine receptors before but not during ischemia does delay contracture (5), and there is evidence that this effect may be A 3 rather than A 1 AR dependent (4) .
Effects of intrinsic A 1 AR activation on postischemic function. Some studies show that adenosine receptor activation during reperfusion affords cardioprotection (6, 7, 35, 47) , largely via A 2 -mediated mechanisms. The weight of evidence favors A 1 AR-mediated protection during ischemia rather than reperfusion (9, 27, 30, 32, 40, 48) . However, this evidence has largely been accumulated via use of exogenous agonists rather than selective antagonists, and there is recent evidence of A 1 AR-mediated protection during reperfusion (34) . We wished to test the hypothesis that A 1 AR activation during ischemia and/or reperfusion is cardioprotective. To address the hypothesis, cardiac A 1 ARs were antagonized during ischemia alone in one group and during reperfusion alone in another group. Functional recovery in hearts receiving DPCPX throughout ischemia alone differs from recovery in hearts not receiving DPCPX at any time (Fig. 1) . Similarly, recovery in hearts receiving DPCPX throughout reperfusion alone differs from recovery in untreated hearts. Because DPCPX is a selective and potent A 1 AR antagonist, these observations show that intrinsic or endogenous A 1 AR activation during ischemia or reperfusion improves recovery. Preischemic treatment had a greater effect on early contractile recovery, yet ultimate effects of both treatment regimes were almost identical after 30 min of reperfusion.
The mechanism(s) by which ischemic A 1 AR activation modifies postischemic function is not known, although there are some similarities with preconditioning in that effects of receptor activation may not be realized until the recovery period. One possible mechanism contributing to effects of ischemic DPCPX treatment involves acceleration of cardiac activity before ischemia. We observed a small (ϳ10%) elevation in preischemic heart rate with A 1 AR blockade, and it is known that significant modification of preischemic metabolic rate can alter responses to ischemia. Although unlikely, we tested whether this change might contribute to altered postischemic recovery. As shown in Figs. 1 and 2 , an equivalent rise in heart rate in untreated hearts had absolutely no effect on ischemic function or postischemic recovery. We conclude that detrimental effects of A 1 AR blockade before and during ischemia are unrelated to the modest 10% elevation in preischemic heart rate.
Reductions in postischemic contractile function reflect Ca 2ϩ overload during reperfusion (18) with impaired myofibrillar sensitivity to Ca 2ϩ (8, 13) . A 1 AR activation by endogenous adenosine may modify sarcolemmal Ca 2ϩ fluxes by activation of ATP-sensitive K ϩ (K ATP ) channels (28, 46) and by more direct inhibition of Ca 2ϩ channels. In support of these possibilities, Fralix et al. (12) have shown that adenosine-mediated protection is associated with reduced cellular Ca 2ϩ accumulation and reduced acidosis, and our recent studies show that A 1 AR-mediated protection in mouse heart involves K ATP channel activation (24) . We have also demonstrated that receptor activation by endogenous adenosine improves myocardial energy state during ischemia-reperfusion in the mouse (23) . Although improved mitochondrial function and energy state may not modify function during ischemia itself, it will reduce Na ϩ and H ϩ accumulation, inhibiting Ca 2ϩ overload during early reperfusion (41) . Such a scheme could contribute to the temporal pattern observed here. The role of glycolysis in these effects remains obscure because A 1 AR activation can enhance (1, 10, 27) or inhibit (11, 12, 14) glycolytic metabolism, protecting by enhanced ATP generation in the former or reduced acidosis in the latter. Because contracture is most directly related to a fall in glycolytic ATP production (29, 36) , the lack of effect of DPCPX and CPA on contracture (Fig. 2) indicates a lack of effect of endogenous or exogenous A 1 AR activation on glycolytic ATP formation during ischemia.
Consistent with a metabolically beneficial action of endogenous adenosine, we have documented worsening of postischemic energy metabolism in rat hearts subjected to low-flow ischemia in the presence of 8-phenyltheophylline (2) . It is interesting to note, however, that no functional change was observed, in contrast to mouse data. Reasons for this difference include the different species studied, nonselectivity of the antagonist used, and the quite different types and severity of insult studied (low-flow versus zero-flow ischemia). Indeed, the level of deenergization in the rat model was modest (only 30-40% reductions in ATP and PCr) (2) compared with almost total loss of ATP and PCr in ischemic mouse heart (23) . Furthermore, contracture in the low-flow rat model is much lower than in globally ischemic mouse heart, and rat hearts recovered to ϳ95% of preischemic function versus only 50-60% in the globally ischemic murine model. It is quite possible that the type and severity of insult, and the level of dysfunction that occurs, may determine whether A 1 AR activation enhances functional recovery.
In terms of the salutary effects of A 1 AR activation during reperfusion, previous studies verify that adenosine receptor activation at this time can reduce cell damage, although the major effect appears to be A 2 receptor mediated with a minor effect of A 1 ARs at this time (7, 33, 47) . However, we show that the ultimate degree of A 1 AR cardioprotection mediated by endogenous adenosine during either ischemia or reperfusion is similar. Only the rate of recovery differs, with ischemic A 1 AR activation apparently improving initial recovery to a greater extent than postischemic A 1 AR activation. The responses to DPCPX are consistent with a predominant effect on postischemic stunning rather than tissue necrosis, because recoveries for control and DPCPX-treated hearts are initially divergent but converge after 30 min of reperfusion and do not appear to plateau. We note that subsequent studies in our laboratory examining 60-min periods of reperfusion reveal that contractile recovery plateaus at ϳ40 min in the present murine model (data not shown). The postischemic recovery pattern observed in the present study (with and without DPCPX) is suggestive of modification of a reversible form of injury. Because there were no differences in postischemic coronary flow between groups, the observed alterations in contractile recovery do not result from differences in coronary reflow.
Experimental limitations. Several experimental limitations deserve mention. The first relates to use of microdialysis in murine myocardium. No previous studies have measured extracellular adenosine in mouse heart during ischemia or applied microdialysis in murine myocardium. Owing to cell damage on probe implantation, we normally employ a 60-to 90-min stabilization period in rat hearts to allow for a decline in extracellular purines toward baseline levels (19) (20) (21) (22) . Here we employed a 40-min stabilization period before ischemia, potentially leading to overestimation of basal purine levels. Compounding this issue, it might be argued that the small size of the mouse heart will contribute to an increased percentage of left ventricular myocytes damaged by implantation of the 300-m probe (relative to larger species). However, probe implantation did not alter left ventricular mechanics, heart rate, or coronary flow (Table 1) . Indeed, we note that hearts in the present study possess levels of contractility generally exceeding those measured in previous perfused murine heart studies. Additionally, preliminary studies revealed no change in myocardial enzyme leakage after probe implantation. Thus the method does not appear to produce an excessive degree of damage in left ventricular myocardium. Importantly, although we recognize that basal levels of adenosine in the mouse may be overestimated by this technique, this does not alter our conclusion regarding lower interstitial adenosine in ischemic mouse versus rat heart. Moreover, because preischemic interstitial adenosine was estimated to be 0.3 M, the value measured during ischemia (1.9 M) will be overestimated (if at all) by Յ15% due to potential lack of stabilization.
A second limitation is the finite period required for washout of interstitial DPCPX in hearts receiving the antagonist before and during ischemia. Thus there will be residual antagonist immediately on reperfusion in this experimental group. We have previously shown that 3 min of perfusion washes Ͼ95% of a large molecule, distributed throughout the extracellular compartment, from the perfused heart (25) . The relatively small DPCPX should therefore be reduced to very low levels within the first 1-2 min of reperfusion, limiting its effects at this time. Nonetheless, given that these first minutes of reperfusion may be important in determining the extent of reperfusion injury, the presence of low levels of antagonist at this time may contribute to reduced recovery in the ischemic DPCPX treatment group. Importantly, effects of ischemic and postischemic DPCPX treatment on diastolic dysfunction differed markedly, and ischemic DPCPX produced a greater reduction in early recovery than postischemic DPCPX, supporting distinct A 1 AR-mediated effects during the two different phases of injury (ischemia versus reperfusion).
In conclusion, the results of the present study demonstrate that activation of A 1 ARs by endogenous adenosine significantly improves functional recovery from ischemia. Functional protection is mediated by intrinsic activation of A 1 ARs both during the ischemic episode itself and during the postischemic period. The ultimate degree of protection provided by intrinsic A 1 AR activation during either period is comparable. These effects are consistent with observed elevations of interstitial adenosine to active levels during ischemia and reperfusion. Our data also demonstrate that intrinsic A 1 AR activation during ischemia does not mod-ify rate or extent of ischemic contracture development, consistent with previous observations in rat hearts treated with selective A 1 AR antagonists (16) but in contrast to previous studies employing less specific antagonists (32, 34) . Data collectively support a role for other adenosine receptors (potentially the A 3 subtype) in inhibition of ischemic contracture or suggest that preischemic adenosine receptor activation may be involved in reducing contracture in hearts pretreated with adenosine agonists. These latter issues deserve further investigation.
